The race to use gene therapy to treat Duchenne muscular dystrophy, a progressive, deadly genetic disease that affects boys, is heating up this week. The FDA just cleared Solid Biosciences to resume clinical testing of a Duchenne gene therapy, a day before Sarepta Therapeutics will report human clinical data from a rival treatment that also uses the approach.
Solid (NASDAQ: SLDB) said this morning that it can restart IGNITE DMD, an early-stage study testing its experimental Duchenne gene therapy SGT-001. The FDA halted the study in March after Solid reported that a patient dosed with the gene therapy was… Read more »
UNDERWRITERS AND PARTNERS